Document Detail

Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
MedLine Citation:
PMID:  11792139     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Many patients with acute coronary syndromes are offered percutaneous coronary intervention. However, the appropriate indications for, and optimal timing of, such procedures are uncertain. We analysed timing of intervention and associated events (death and myocardial infarction) in the PURSUIT trial in which 9461 patients received a platelet glycoprotein IIb/IIIa inhibitor, eptifibatide, or placebo for 72 h. Other treatment was left to the investigators. 2430 patients underwent percutaneous coronary intervention within 30 days. Four groups were distinguished, who underwent percutaneous coronary intervention on day 1; on days 2 or 3; at 4 to 7 days; or between 8 until 30 days, for eptifibatide- and placebo-treated patients. RESULTS: The four groups treated with placebo demonstrated total 30-day events of 15.9% for day 1 percutaneous coronary intervention, 17.7%, 15.0% and 18.2%, respectively, for successive intervals of later intervention. Later intervention was associated with more pre-procedural events (2.2% to 13.7%, P=0.001) which was balanced by a decrease in procedure-related events (12.1 to 3.1%, P=0.001), while the overall 30-day event rates were similar. Eptifibatide-treated patients with percutaneous coronary intervention on day 1 had the lowest rate of 30-day events (9.2%, P<0.05 vs other groups). In this group, pre-procedural risk was only 0.3%, while percutaneous coronary intervention on eptifibatide treatment was associated with low procedural risk (7.2%). The total 30-day event rate for later percutaneous coronary intervention in patients receiving eptifibatide was 14.0 on days 2 and 3, 15.0% for days 4 to 7 and 17.4% for days 7 to 30, respectively. CONCLUSION: Patients treated with a platelet glycoprotein IIb/IIIa receptor blocker, and early percutaneous coronary intervention (within 24 h) had the lowest event rate in this post hoc analysis. Thus 'watchful waiting' may not be the optimal strategy. Rather an early invasive strategy with percutaneous coronary intervention under protection of a platelet glycoprotein IIb/IIIa receptor blocker should be considered in selected patients. Randomized trials are warranted to verify this issue.
E Ronner; E Boersma; K M Akkerhuis; R A Harrington; A M Lincoff; J W Deckers; K Karsch; N S Kleiman; A Vahanian; E J Topol; R M Califf; M L Simoons
Related Documents :
25065469 - Adoption of cardiac resynchronization therapy in heart failure patients with post-cardi...
24975909 - Natriuretic peptides in heart failure with preserved ejection fraction.
17102829 - Transfer for urgent percutaneous coronary intervention early after thrombolysis for st-...
16606819 - Clopidogrel to treat patients with non-st-segment elevation acute coronary syndromes af...
18533739 - Management of st-elevation myocardial infarction: an update on pharmacoinvasive recanal...
23702289 - Percutaneous left atrial appendage closure using a pfo closure device.
725619 - Role of the psyche in recovery from myocardial infarction.
24022659 - Insulin resistance is a major determinant of myocardial blood flow impairment in angina...
15227459 - Transatrial closure of postinfarction ventricular septal defect.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European heart journal     Volume:  23     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-01-16     Completed Date:  2002-05-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  239-46     Citation Subset:  IM    
Copyright Information:
Copyright 2001 The European Society of Cardiology.
University Hospital Rotterdam, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Angioplasty, Transluminal, Percutaneous Coronary*
Combined Modality Therapy
Coronary Disease / complications,  mortality,  therapy*
Endpoint Determination
Follow-Up Studies
Middle Aged
Peptides / antagonists & inhibitors,  therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*,  therapeutic use*
Platelet Glycoprotein GPIb-IX Complex / antagonists & inhibitors*,  therapeutic use*
Platelet Membrane Glycoproteins*
Postoperative Complications / etiology,  mortality
Survival Analysis
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Peptides; 0/Placebos; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Platelet Glycoprotein GPIb-IX Complex; 0/Platelet Membrane Glycoproteins; 0/eptifibatide; 0/glycoprotein receptor GPIb-IX
Comment In:
Eur Heart J. 2002 Sep;23(17):1404; author reply 1404   [PMID:  12269269 ]
Eur Heart J. 2002 Feb;23(3):194-7   [PMID:  11792132 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarctio...
Next Document:  Discrepancy between angiography and intravascular ultrasound when analysing small coronary arteries.